Pathophysiology and treatment of systemic amyloidosis

Nature Reviews Nephrology

Volumn 9, Issue 10, 2013, Pages 574-586

  Gillmore, Julian D ^a   Hawkins, Philip N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; AMIODARONE; AMYLOID; AMYLOID A PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; CALCIUM ANTAGONIST; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIFLUNISAL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPRODISATE; LENALIDOMIDE; LOOP DIURETIC AGENT; MELPHALAN; MIDODRINE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; TAFAMIDIS; THALIDOMIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

AMYLOIDOSIS; CARDIAC IMAGING; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIALYSIS; DNA DETERMINATION; DRUG MEGADOSE; FAMILIAL AMYLOID POLYNEUROPATHY; FIBER; HEART; HEART AMYLOIDOSIS; HEREDITARY SYSTEMIC AMYLOIDOSIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; KIDNEY; KIDNEY AMYLOIDOSIS; KIDNEY FUNCTION; KINETICS; NEPHROTIC SYNDROME; ORGAN PRESERVATION; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SCINTIGRAPHY; TISSUE INJURY;

AMYLOIDOSIS; HUMANS; KIDNEY DISEASES;

EID: 84884669084     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.171     Document Type: Review

References (135)

1. Sipe, J. D. et al. Amyloid fibril protein nomenclature: 2010 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 17, 101-104 (2010
2. Merlini, G. & Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583-596 (2003
3. Obici, L., Raimondi, S., Lavatelli, F., Bellotti, V. & Merlini, G. Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis Rheum. 61, 1435-1440 (2009
4. Saraiva, M. J. Hereditary transthyretin amyloidosis: Molecular basis and therapeutical strategies. Exp. Rev. Mol. Med. 4, 1-11 (2002
5. Cohen, A. S. & Calkins, E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183, 1202-1203 (1959
6. Eanes, E. D. & Glenner, G. G. X ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16, 673-677 (1968
7. Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Ann. Rev. Biochem. 75, 333-366 (2006
8. Greenwald, J. & Riek, R. Biology of amyloid: Structure, function, and regulation. Structure 18, 1244-1260 (2010
9. Pepys, M. B. et al. Amyloid P component. A critical review. Amyloid 4, 274-295 (1997
10. Bodin, K. et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468, 93-97 (2010
11. Li, J. P. et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl Acad. Sci. USA 102, 6473-6477 (2005
12. Motamedi-Shad, N., Monsellier, E., Torrassa, S., Relini, A. & Chiti, F. Kinetic analysis of amyloid formation in the presence of heparan sulfate: Faster unfolding and change of pathway. J. Biol. Chem. 284, 29921-29934 (2009
13. Ren, R. et al. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. J. Biol. Chem. 285, 37672-37682 (2010
14. Martin, D. J. & Ramirez-Alvarado, M. Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. Biophys. Chem. 158, 81-89 (2011
15. Elimova, E., Kisilevsky, R. & Ancsin, J. B. Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: Evidence for a proamyloidogenic histidine molecular switch. FASEB J. 23, 3436-3448 (2009
16. Noborn, F. et al. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc. Natl Acad. Sci. USA 108, 5584-5589 (2011
17. Ancsin, J. B. Amyloidogenesis: Historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 10, 67-79 (2003
18. Calero, M., Rostagno, A. & Ghiso, J. Search for amyloid-binding proteins by affinity chromatography. Methods Mol. Biol. 849, 213-223 (2012
19. Hawkins, P. N. & Pepys, M. B. A primed state exists in vivo following histological regression of amyloidosis. Clin. Exp. Immunol. 81, 325-328 (1990
20. Relini, A. et al. Collagen plays an active role in the aggregation of β2 microglobulin under physio-pathological conditions of dialysis-related amyloidosis. J. Biol. Chem. 281, 16521-16529 (2006
21. Comenzo, R. L., Zhang, Y., Martinez, C., Osman, K. & Herrera, G. A. The tropism of organ involvement in primary systemic amyloidosis: Contributions of Ig V L germ line gene use and clonal plasma cell burden. Blood 98, 714-720 (2001
22. Perfetti, V. et al. Analysis of V λ J λ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (λ III) as a new amyloid-associated germline gene segment. Blood 100, 948-953 (2002
23. Abraham, R. S. et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101, 3801-3808 (2003
24. Pepys, M. B. Amyloidosis. Annu. Rev. Med. 57, 223-241 (2006
25. Sousa, M. M., Cardoso, I., Fernandes, R., Guimaraes, A. & Saraiva, M. J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy - evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159, 1993-2000 (2001
26. Andersson, K., Olofsson, A., Nielsen, E. H., Svehag, S. E. & Lundgren, E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem. Biophys. Res. Commun. 294, 309-314 (2002
27. Hartley, D. M. et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884 (1999
28. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448-6453 (1998
29. Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002
30. Shi, J. et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway. Proc. Natl Acad. Sci. USA 107, 4188-4193 (2010
31. Liao, R. L. et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104, 1594-1597 (2001
32. Brenner, D. A. et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circulation Res. 94, 1008-1010 (2004
33. Silveira, J. R. et al. The most infectious prion protein particles. Nature 437, 257-261 (2005
34. Palladini, G. et al. Circulating amyloidogenic free light chains and serum N terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107, 3854-3858 (2006
35. Pinney, J. H. et al. Systemic amyloidosis in England: An epidemiological study. Br. J. Haematol. 161, 525-532 (2013
36. Mesquita, M. et al. Renal biopsy findings in Belgium: A retrospective single center analysis. Acta Clin. Belg. 66, 104-109 (2011
37. Tufveson, G. et al. The combined report on regular dialysis and transplantation in Europe. XIX 1988. Nephrol. Dial. Transplant. 4, 1-30 (1989
38. Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564-569 (2002
39. Merlini, G. & Stone, M. J. Dangerous small B cell clones. Blood 108, 2520-2530 (2006
40. Obici, L., Perfetti, V., Palladini, G., Moratti, R. & Merlini, G. Clinical aspects of systemic amyloid diseases. Biochim. Biophys. Acta 1753, 11-22 (2005
41. Witzig, T. E., Timm, M., Larson, D., Therneau, T. & Greipp, P. R. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br. J. Haematol. 104, 131-137 (1999
42. Rajkumar, S. V., Gertz, M. A. & Kyle, R. A. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 82, 1501-1505 (1998
43. de Beer, F. C. et al. Serum amyloid A protein (SAA) concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 2, 231-234 (1982
44. Schnitzer, T. J. & Ansell, B. M. Amyloidosis in juvenile chronic polyarthritis. Arthritis Rheum. 20, 245-252 (1977
45. Myllykangas-Luosujärvi, R., Aho, K., Kautiainen, H. & Hakala, M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatol. 38, 499-503 (1999
46. Filipowicz-Sosnowska, A. M., Roztropowicz-Denisiewicz, K., Rosenthal, C. J. & Baum, J. The amyloidosis of juvenile rheumatoid arthritis - comparative studies in Polish and American children. I. Levels of serum SAA protein. Arthritis Rheum. 21, 699-703 (1978
47. Svantesson, H., Akesson, A., Eberhardt, K. & Elborgh, R. Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study. Scand. J. Rheumatol. 12, 139-144 (1983
48. Laiho, K., Tiitinen, S., Kaarela, K., Helin, H. & Isomaki, H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin. Rheumatol. 18, 122-123 (1999
49. Immonen, K. et al. Decline in the incidence of renal failure due to amyloidosis associated with inflammatory rheumatic diseases. Amyloid 18 (Suppl. 1), 229-230 (2011
50. Panizo, N., Rivera, F. & Lopez-Gomez, J. M. Decreasing incidence of AA amyloidosis in Spain. Eur. J. Clin. Invest. 43, 767-773 (2013
51. Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361-2371 (2007
52. Schwalbe, S et al. β2 microglobulin associated amyloidosis: A vanishing complication of long-term hemodialysis? Kidney Int. 52, 1077-1083 (1997
53. Benson, M. D., James, S., Scott, K., Liepnieks, J. J. & Kluve-Beckerman, B. Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int. 74, 218-222 (2008
54. Murphy, C. L. et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: A case series. Am. J. Kidney Dis. 56, 1100-1107 (2010
55. Larsen, C. P., Walker, P. D., Weiss, D. T. & Solomon, A. Prevalence and morphology of leukocyte chemotactic factor 2 associated amyloid in renal biopsies. Kidney Int. 77, 816-819 (2010
56. Kyle, R. A. & Gertz, M. A. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin. Hematol. 32, 45-59 (1995
57. Pinney, J. H. et al. Outcome in renal AL amyloidosis following chemotherapy. J. Clin. Oncol. 29, 674-681 (2011
58. Drueke, T. B. & Massy, Z. A. Beta2-microglobulin. Semin. Dial. 22, 378-380 (2009
59. Nelson, S. R. et al. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet 338, 335-339 (1991
60. Jimenez, R. E. et al. Development of gastrointestinal β2-microglobulin amyloidosis correlates with time on dialysis. Am. J. Surg. Pathol. 22, 729-735 (1998
61. Sattianayagam, P. T. et al. Hereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation. J. Intern. Med. 272, 36-44 (2012
62. Obici, L. et al. Liver biopsy discloses a new apolipoprotein A I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 126, 1416-1422 (2004
63. Gregorini, G. et al. Renal apolipoprotein A I amyloidosis: A rare and usually ignored cause of hereditary tubulointerstitial nephritis. J. Am. Soc. Nephrol. 16, 3680-3686 (2005
64. Gillmore, J. D. et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A α-chain amyloidosis. J. Am. Soc. Nephrol. 20, 444-451 (2009
65. Sethi, S. et al. Medullary amyloidosis associated with apolipoprotein A IV deposition. Kidney Int. 81, 201-206 (2012
66. Lobato, L. et al. End-stage renal disease in familial amyloidosis ATTR Val30Met: A definitive indication to combined liver-kidney transplantation Transplant. Proc. 35, 1116-1120 (2003
67. Valleix, S. et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N. Engl. J. Med. 366, 2276-2283 (2012
68. Rocken, C., Schwotzer, E. B., Linke, R. P. & Saeger, W. The classification of amyloid deposits in clinicopathological practice. Histopathology 29, 325-335 (1996
69. van Gameren, I., Hazenberg, B. P., Bijzet, J. & van Rijswijk, M. H. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 54, 2015-2021 (2006
70. Fish, R. et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin. J. Am. Soc. Nephrol. 5, 1977-1980 (2010
71. Arbustini, E. et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 4, 157-170 (1997
72. Vrana, J. A. et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114, 4957-4959 (2009
73. Lavatelli, F. et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol. Cell. Proteomics 7, 1570-1583 (2008
74. Hawkins, P. N., Myers, M. J., Lavender, J. P. & Pepys, M. B. Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component. Lancet 1, 1413-1418 (1988
75. Falk, R. H. Diagnosis and management of the cardiac amyloidoses. Circulation 112, 2047-2060 (2005
76. Westenberg, J. J. CMR for Assessment of Diastolic Function. Curr. Cardiovasc. Imaging Rep. 4, 149-158 (2011
77. Hosch, W. et al. MR relaxometry of myocardial tissue: Significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest. Radiol. 42, 636-642 (2007
78. Sparrow, P., Amirabadi, A., Sussman, M. S., Paul, N. & Merchant, N. Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J. Magn. Reson. Imaging 30, 942-946 (2009
79. Maceira, A. M. et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111, 186-193 (2005
80. Maceira, A. M., Prasad, S. K., Hawkins, P. N., Roughton, M. & Pennell, D. J. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J. Cardiovasc. Magn. Reson. 10, 54 (2008
81. Rapezzi, C. et al. Usefulness and limitations of 99mTc 3, 3 diphosphono 1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur. J. Nucl. Med. Mol. Imaging 38, 470-478 (2011
82. Benson, M. D. Ostertag revisited: The inherited systemic amyloidoses without neuropathy. Amyloid 12, 75-87 (2005
83. Merlini, G., Seldin, D. C. & Gertz, M. A. Amyloidosis: Pathogenesis and new therapeutic options. J. Clin. Oncol. 29, 1924-1933 (2011
84. Gillmore, J. D., Lovat, L. B., Persey, M. R., Pepys, M. B. & Hawkins, P. N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358, 24-29 (2001
85. Gertz, M. & Merlini, G. Definition of organ involvement and response to treatment in AL amyloidosis: An updated consensus opinion. Amyloid 17 (Suppl. 1), 48-49 (2010
86. Comenzo, R. L. et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26, 2317-2325 (2012
87. Gertz, M. A. et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 92, 1415-1418 (2007
88. Palladini, G. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J. Clin. Oncol. 30, 4541-4549 (2012
89. Lachmann, H. J. et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 122, 78-84 (2003
90. Wechalekar, A. D. et al. N terminal fragment of brain natriuretic peptide (NT-ProBNP) - A new response criterion in AL amyloidosis. Amyloid 17 (Suppl. 1), 84-85 (2010
91. Skinner, M. et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8 year study. Ann. Intern. Med. 140, 85-93 (2004
92. Cibeira, M. T. et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood 118, 4346-4352 (2011
93. Gertz, M. A. et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 48, 557-561 (2013
94. Gertz, M. A. et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol. Dial. Transplant. 24, 3132-3137 (2009
95. Dember, L. M. et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann. Intern. Med. 134, 746-753 (2001
96. Berglund, K., Thysell, H. & Keller, C. Results, principles and pitfalls in the management of renal AA amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J. Rheumatol. 20, 2051-2057 (1993
97. Bergesio, F. et al. Renal involvement in systemic amyloidosis: An Italian collaborative study on survival and renal outcome. Nephrol. Dial. Transplant. 23, 941-951 (2008
98. Tan, S. Y. et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int. 50, 282-289 (1996
99. Traut, M. et al. Increased binding of β2 microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced β2 microglobulin concentrations. Results of a cross-over study. Blood Purif. 25, 432-440 (2007
100. Gillmore, J. D. et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am. J. Transplant. 6, 2342-2347 (2006
101. Coelho, T. et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 79, 785-792 (2012
102. Gertz, M. A., Kyle, R. A. & O'Fallon, W. M. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch. Intern. Med. 152, 2245-2250 (1992
103. Moroni, G. et al. Chronic dialysis in patients with systemic amyloidosis: The experience in northern Italy. Clin. Nephrol. 38, 81-85 (1992
104. Immonen, K. et al. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases - Data from the Finnish national registry for kidney diseases. J. Rheumatol. 35, 1334-1338 (2008
105. Lachmann, H. J. et al. Survival on dialysis and outcome after renal transplantation in AA amyloidosis. Amyloid 17 (Suppl. 1), 73 (2010
106. Sattianayagam, P. et al. Solid organ transplantation in AL amyloidosis. J. Am. Transplant. 10, 2124-2131 (2010
107. Leung, N. et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am. J. Transplant. 5, 1660-1670 (2005
108. Emiroglu, R. et al. Effect of amyloidosis on long-term survival in kidney transplantation. Transplant. Proc. 37, 2967-2968 (2005
109. Sherif, A. M. et al. Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am. J. Kidney Dis. 42, 370-375 (2003
110. Jacob, E. T., Bar-Nathan, N., Shapira, Z. & Gafni, J. Renal transplantation in the amyloidosis of familial Mediterranean fever. Experience of ten cases. Arch. Intern. Med. 139, 1135-1138 (1979
111. Gillmore, J. D., Madhoo, S., Pepys, M. B. & Hawkins, P. N. Renal transplantation for amyloid end-stage renal failure -insights from serial serum amyloid P component scintigraphy. Nucl. Med. Commun. 21, 735-740 (2000
112. Majumder, B. et al. "A case of cardiac amyloidosis with syncope". Indian Heart J. 62, 171-172 (2010
113. Palladini, G. et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103, 2936-2938 (2004
114. Soni, A. & LeLorier, P. Sudden death in nondilated cardiomyopathies: Pathophysiology and prevention. Curr. Heart Fail. Rep. 2, 118-123 (2005
115. Kristen, A. V. et al. Prophylactic implantation of cardioverter- defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5, 235-240 (2008
116. Lin, G., Dispenzieri, A., Kyle, R., Grogan, M. & Brady, P. A. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J. Cardiovasc. Electrophysiol. 24, 793-798 (2013
117. Dubrey, S. W. et al. Long term results of heart transplantation in patients with amyloid heart disease. Heart 85, 202-207 (2001
118. Maurer, M. S. et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplant. 83, 539-545 (2007
119. Dey, B. R. et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplant. 90, 905-911 (2010
120. Gillmore, J. D. et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107, 1227-1229 (2006
121. Phipps, J. E. et al. Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp. Hematol. 38, 1006-1013 (2010
122. Benson, M. D. et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33, 609-618 (2006
123. Kluve-Beckerman, B. et al. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid 18, 136-146 (2011
124. US National Library of Medicine. ClinicalTrials.gov [online] http://www.clinicaltrials.gov/ct2/results?term=ATTR+amyloidosis (2013
125. Sekijima, Y., Kelly, J. W. & Ikeda, S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr. Pharm. Des. 14, 3219-3230 (2008
126. Dember, L. M. et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N. Engl. J. Med. 356, 2349-2360 (2007
127. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002
128. Gillmore, J. D. et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br. J. Haematol. 148, 760-767 (2010
129. Solomon, A., Weiss, D. T. & Wall, J. S. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother. Radiopharm. 18, 853-860 (2003
130. Merlini, G. et al. Interaction of the anthracycline 4Ŷ iodo 4Ŷ-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc. Natl Acad. Sci. USA 92, 2959-2963 (1995
131. Cardoso, I. & Saraiva, M. J. Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB J. 20, 234-239 (2006
132. Sattianayagam, P. T. et al. A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica 98, 136-140 (2013
133. Venner, C. P. et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119, 4387-4390 (2012
134. Dispenzieri, A. et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361, 1787-1789 (2003
135. Lovat, L. B., Persey, M. R., Madhoo, S., Pepys, M. B. & Hawkins, P. N. The liver in systemic amyloidosis: Insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 42, 727-734 (1998